HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors.

AbstractOBJECTIVES:
To assess the efficacy of desmopressin plus oxybutynin and compare two starting dosages of desmopressin (120 and 240 µg) in a randomized, double-blinded, placebo-controlled trial for children with monosymptomatic nocturnal enuresis (MNE) resistant to desmopressin. The predictive factors of children with MNE responsive to desmopressin and combination therapy were also evaluated.
PATIENTS AND METHODS:
Our sample included 206 patients aged between 6 and 13 (mean age 10.6 ± 2.9 years), 117 males. All patients were required to have MNE. The patients were randomly divided into two groups: the first group was given oral melt 120 µg and the second group 240 µg, for 2 weeks. All patients who had experienced failure of treatment with sublingually administered desmopressin alone were given either desmopressin plus 5 mg oxybutynin or desmopressin plus placebo in a randomized, double-blinded trial for 4 weeks. As predictive factors, bladder volume and wall thickness index, nocturnal polyuria and voiding latency were considered.
RESULTS:
There was no significant difference between the 120 µg and 240 µg patients in terms of response. The oxybutynin group showed a higher rate of full and partial responses (45% success) compared with the placebo group (17% success), P < 0.01. The responders to combined oxybutynin and desmopressin had significantly lower bladder volume and wall thickness index than the other patients.
CONCLUSIONS:
Our findings highlight that anticholinergic agents may play an important role for a subset of children with enuresis who have a restricted bladder capacity and thickened bladder wall. Ultrasonography-measured bladder variables can provide useful predictive clues for MNE. Predictive factors can help to differentiate treatment subtypes and guide clinical management in primary nocturnal enuresis.
AuthorsPaolo Montaldo, Lucia Tafuro, Monica Rea, Valeria Narciso, Azzurra C Iossa, Roberto Del Gado
JournalBJU international (BJU Int) Vol. 110 Issue 8 Pt B Pg. E381-6 (Oct 2012) ISSN: 1464-410X [Electronic] England
PMID22313792 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.
Chemical References
  • Antidiuretic Agents
  • Mandelic Acids
  • Deamino Arginine Vasopressin
  • oxybutynin
Topics
  • Adolescent
  • Antidiuretic Agents (therapeutic use)
  • Child
  • Deamino Arginine Vasopressin (therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Mandelic Acids (therapeutic use)
  • Nocturnal Enuresis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: